Improving Survival In Oncogene Driven Lung Cancer

TOGA Podcast

English - November 10, 2020 00:10 - 30 minutes - 27.7 MB
Medicine Health & Fitness lung cancer oncology toga Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Next Episode: Redefining Survival In Lung Cancer: Meet Alexandra

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.